Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis determine a high cost to the Italian National Health Service (INHS). The availability of biological drugs – among which etanercept – greatly improved treatment efficacy. The biological drugs are an expensive resource. Et...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-04-01
|
| Series: | Global & Regional Health Technology Assessment |
| Online Access: | https://doi.org/10.1177/2284240318766804 |